The Ross procedure: an excellent option in the right hands

Bowdish, Michael E.; Kumar, Sandeep; Starnes, Vaughn A.

doi:10.21037/atm.2016.11.32

Cited by 7 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Ross procedure, firstly established by Donald Ross in 1967 49 , consists in the replacement of a diseased aortic root with the patient's autologous pulmonary valve, while a cH is implanted at pulmonary position to restore the right ventricular outflow track 50 . This technique was developed to overcome the lack of durable valve replacements for young patients affected by diseased aortic valves.…”

Section: Autograft (Ross Procedure)mentioning

confidence: 99%

Next-generation tissue-engineered heart valves with repair, remodelling and regeneration capacity

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Autograft (Ross Procedure)mentioning

confidence: 99%

Next-generation tissue-engineered heart valves with repair, remodelling and regeneration capacity

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Autograft valves are prepared using the patient's own tissues, by replacing the aortic valve with the autologous pulmonary valve of the patient (Ross procedure) [73]. In the same procedure, for a rapid restoration of blood flow in the exit right ventricle tract, a cryopreserved homograft is implanted.…”

Section: Bioprosthetic Valvesmentioning

confidence: 99%

Natural Polymers in Heart Valve Tissue Engineering: Strategies, Advances and Challenges

Ciolacu¹,

Nicu²,

Ciolacu

2022

Biomedicines

View full text Add to dashboard Cite

In the history of biomedicine and biomedical devices, heart valve manufacturing techniques have undergone a spectacular evolution. However, important limitations in the development and use of these devices are known and heart valve tissue engineering has proven to be the solution to the problems faced by mechanical and prosthetic valves. The new generation of heart valves developed by tissue engineering has the ability to repair, reshape and regenerate cardiac tissue. Achieving a sustainable and functional tissue-engineered heart valve (TEHV) requires deep understanding of the complex interactions that occur among valve cells, the extracellular matrix (ECM) and the mechanical environment. Starting from this idea, the review presents a comprehensive overview related not only to the structural components of the heart valve, such as cells sources, potential materials and scaffolds fabrication, but also to the advances in the development of heart valve replacements. The focus of the review is on the recent achievements concerning the utilization of natural polymers (polysaccharides and proteins) in TEHV; thus, their extensive presentation is provided. In addition, the technological progresses in heart valve tissue engineering (HVTE) are shown, with several inherent challenges and limitations. The available strategies to design, validate and remodel heart valves are discussed in depth by a comparative analysis of in vitro, in vivo (pre-clinical models) and in situ (clinical translation) tissue engineering studies.

show abstract

“…Additionally, a few Ross procedures (subcoronary inclusion technique), also known as pulmonary autograft procedures, have successfully treated QAV while reducing aortic root dilation risk [ 69 ]. Compared with traditional mechanical or bioprosthetic replacements, autografting a patient’s own pulmonary valve (identical in size, shape, and strength to their aortic valve) minimizes future valve re-replacement probability and does not require lifetime blood thinner medication use [ 70 ]. Manouguian technique (posterior aortic annulus enlargement) was once reported on a Hurwitz and Roberts’ type A QAV patient with narrow annulus alongside aortic steno-insufficiency and mitral insufficiency [ 25 ].…”

Section: Managementmentioning

confidence: 99%

Quadricuspid Aortic Valve: An Introduction for Clinicians

Saith

Murthy

2022

Cardiol Res

View full text Add to dashboard Cite

Quadricuspid aortic valve (QAV) is a congenital heart anomaly in which the aortic valve has four cusps of various size possibilities, as opposed to the three symmetrical cusps generally observed. This cardiac valvular abnormality is rarely identified, with an estimated incidence rate of 0.013% to 0.043%, although recent technological advancements in diagnostics have contributed to an increase in detection. Historically, it had been typically encountered during open heart surgery or postmortem; however, it is presently diagnosed primarily via ultrasound echocardiography, and could go undetected unless specifically considered. It was first reported by Babington in 1847, and since then approximately 300 cases have been published. This condition is sporadically associated with additional congenital cardiovascular defects, with coronary artery irregularities being the most common. In more than half of published QAV incidences it has led to the progressive development of aortic regurgitation (AR) usually sans aortic stenosis, particularly amongst elderly patients, often requiring surgical intervention after 50 years of age. A fifth of total instances, but two-thirds of instances with AR, warrant surgery seldom amidst complications, with reconstructive tricuspidization preferred over valve replacement.

show abstract

The Ross procedure: an excellent option in the right hands

Cited by 7 publications

References 11 publications

Next-generation tissue-engineered heart valves with repair, remodelling and regeneration capacity

Next-generation tissue-engineered heart valves with repair, remodelling and regeneration capacity

Natural Polymers in Heart Valve Tissue Engineering: Strategies, Advances and Challenges

Quadricuspid Aortic Valve: An Introduction for Clinicians

Contact Info

Product

Resources

About